You are here: Industry Insights > NICE

News List

Discount helps NICE flip-flop on Teva's severe asthma contender, Cinqair fiercepharma
July 21, 2017
There’s still no word on whether Teva has landed AstraZeneca CEO Pascal Soriot or if he is staying put, as later reports said. But in the meantime, the drugmaker got some good news Thursday on the respiratory front.
NICE recommends cabozantinib for advanced renal cell cancer europeanpharmaceuticalreview
July 11, 2017
The National Institute for Health and Care Excellence (NICE) has issued final guidance recommending cabozantinib for some kidney cancer patients
NICE recommends Alexion’s Strensiq for hypophosphatasia treatment pharmaceutical-technology
July 10, 2017
UK’s National Institute for Health and Care Excellence (NICE) has recommended the use of Alexion Pharma’s Strensiq (asfotase alfa) drug for the treatment of people with paediatric-onset hypophosphatasia.
NICE agrees approval deal for ultra-rare juvenile bone disease pharmafile
July 06, 2017
NICE has announced that it has decided to approve Alexion Pharma’s Strensiq (asfotase alfa) for the treatment of ultra-rare disease paediatric-onset hypophosphatasia...
NICE recommends Lilly’s Baricitinib (Olumiant) to treat rheumatoid arthritis europeanpharmaceuticalreview
July 05, 2017
Baricitinib is the first JAK inhibitor to be recommended by NICE to treat rheumatoid arthritis in adults who have not responded to conventional therapy…
Pfizer facing NICE showdown over leukaemia drug pharmaphorum
July 05, 2017
Pfizer’s Besponsa leukaemia drug has been approved in Europe, but the company is heading for a showdown with England’s NICE, which has said in a draft decision that the medicine it is too expensive for regular NHS funding.
NICE recommends Lilly’s Baricitinib (Olumiant) to treat rheumatoid arthritis europeanpharmaceuticalreview
July 05, 2017
Baricitinib is the first JAK inhibitor to be recommended by NICE to treat rheumatoid arthritis in adults who have not responded to conventional therapy…
NICE approves AstraZeneca’s COPD drug europeanpharmaceuticalreview
July 04, 2017
The National Institute for Health and Care Excellence (NICE) has published draft guidance recommending roflumilast (Daxas, AstraZeneca) for chronic obstructive pulmonary disease (COPD).
NICE approves AstraZeneca’s COPD drug europeanpharmaceuticalreview
July 04, 2017
The National Institute for Health and Care Excellence (NICE) has published draft guidance recommending roflumilast (Daxas, AstraZeneca) for chronic obstructive pulmonary disease (COPD).
Final NICE nod for Sanofi’s Gaucher therapy pharmatimes
June 30, 2017
Sanofi’s Cerdelga can now be funded on the NHS in England and Wales to treat type 1 Gaucher disease

Previous page 1 2 3 4 5 6 7 8 9 10 ... 41 42 Next page